Molbio Diagnostics Eyes ₹940 Crore Through IPO for Expansion
Molbio Diagnostics plans to raise ₹940 crore through an IPO to fund capital expenditures and reduce promoter stake.
Molbio Diagnostics, a key player in the molecular diagnostics sector, is set to launch an initial public offering (IPO) aimed at raising ₹940 crore. The company intends to use ₹200 crore from the fresh issue to bolster its capital expenditures, while the remaining ₹740 crore will be generated through an offer for sale, reducing the promoter stake from 46.6% to 43%.
Financial Growth and Market Presence
Founded in 2000, Molbio Diagnostics has established a robust global presence with six manufacturing facilities in India and operations extending to over 90 countries. The company's revenue has shown significant growth, primarily driven by its tuberculosis diagnostic test kits, which account for a substantial portion of its sales.
Between fiscal years 2024 and 2026, Molbio reported a 31.5% increase in revenue, reaching ₹1,445.7 crore, and a 40.2% rise in net profit to ₹164.1 crore. The company’s EBITDA grew by 33.2% to ₹328.2 crore, with the EBITDA margin improving slightly to 22.6% in FY26 from 22% in FY24.
Product Portfolio and Strategic Collaborations
Molbio's product lineup includes the 'Truenat' platform, a portable diagnostic system designed for use in resource-limited settings, providing accurate test results within an hour. The company offers molecular testing solutions for over 30 diseases and has developed 43 diagnostic assays.
Government and international aid agencies contribute significantly to Molbio's revenue, accounting for over 80%. The company also collaborates strategically to offer radiology, digital pathology, and breast health screening solutions through its subsidiaries.
Investment Considerations
The IPO positions Molbio Diagnostics in a competitive light, with its price-earnings (P/E) ratio set at up to 57, based on post-IPO equity and FY26 net profit. While the company does not have directly comparable listed peers in India, other firms in the healthcare diagnostics and medical device sector, such as Poly Medicure and Dr. Lal PathLabs, have P/E multiples ranging from 54 to 81.
For investors with a high-risk appetite, Molbio's IPO presents an opportunity for long-term growth, given its strong financial performance and expansive market reach. However, the concentration of revenue from a few top clients and reliance on government contracts could pose risks.